![Elisabeth de Darkó](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Elisabeth de Darkó
Keine laufenden Positionen mehr
Profil
Elisabeth de Darkó served as the Chief Executive Officer of Valderm ApS from 2006 to 2014.
She also worked as the Director of Medical & Regulatory Affairs at Yamanouchi Nordic.
Ehemalige bekannte Positionen von Elisabeth de Darkó
Unternehmen | Position | Ende |
---|---|---|
Yamanouchi Nordic | Technik-/Wissenschafts-/F&E-Leiter | - |
Valderm ApS
![]() Valderm ApS Pharmaceuticals: MajorHealth Technology Valderm ApS is focused on the development of the second generation anthracycline valrubicin for innovative once daily topical treatment of hyper proliferative skin diseases e.g. psoriasis. Preclinical studies have confirmed the anti-proliferative effect of valrubicin and an attractive safety profile upon repeated topical applications has been documented. The company was founded in 2003 and is headquartered in Lyngby, Denmark. | Vorstandsvorsitzender | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Private Unternehmen | 2 |
---|---|
Valderm ApS
![]() Valderm ApS Pharmaceuticals: MajorHealth Technology Valderm ApS is focused on the development of the second generation anthracycline valrubicin for innovative once daily topical treatment of hyper proliferative skin diseases e.g. psoriasis. Preclinical studies have confirmed the anti-proliferative effect of valrubicin and an attractive safety profile upon repeated topical applications has been documented. The company was founded in 2003 and is headquartered in Lyngby, Denmark. | Health Technology |
Yamanouchi Nordic |